, /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced contiguous that Eisai and Washington University School of Medicine successful St. Louis person entered into a broad probe collaboration statement aiming to make imaginable caller treatments for neurodegenerative disorders, including Alzheimer's illness (AD) and Parkinson's illness (PD).
Washington University is satellite starring successful probe connected prevention, diagnosis, biomarkers and attraction of neurodegenerative diseases. The 2 organizations person been collaborating successful AD research. The Phase II/III Tau NexGen Study conducted by the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by the University's School of Medicince, is exploring the safety, tolerability, biomarkers and cognitive efficacy of Eisai's anti-MTBR (microtubule binding region) tau antibody E2814 for the attraction of dominantly inherited Alzheimer's illness (DIAD). In this study, the anti-amyloid beta (Aβ) protofibril antibody lecanemab (generic name, improvement code: BAN2401) was selected arsenic the inheritance anti-amyloid agent.
The collaboration strategically combines Washington University scientists' expertise successful the cardinal and objective probe successful neurodegenerative diseases, specified arsenic dementia, with Eisai's extended acquisition successful cause find and development. Using quality biology, the purpose is to make aggregate caller therapeutic candidates arsenic good arsenic observe and place biomarkers wrong the adjacent 5 years. Eisai volition person the enactment rights to make and commercialize immoderate compounds and biomarkers that conscionable definite criteria successful presumption of probe and improvement milestones. In the lawsuit that Eisai chooses to workout the options, Eisai volition wage Washington University milestone payments and royalties connected aboriginal income of each licensed compounds.
Dr. Teiji Kimura, Ph.D., Academia and Industry Alliance Officer, Deep Human Biology Learning (DHBL) Office of Eisai, commented, "Patients surviving with neurodegenerative diseases, including Alzheimer's illness and Parkinson's disease, conflict with captious unmet aesculapian needs, which is the crushed neurology is simply a cardinal therapeutic country for Eisai. By collaborating with world-leading probe institutions specified arsenic Washington University successful St. Louis, Eisai is moving to fulfill our human wellness care ngo and supply imaginable caller and targeted disease-modifying therapies with the eventual extremity of achieving a satellite escaped of neurodegenerative disease."
Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120
Eisai Inc (U.S.)
Libby Holman 201-753-1945
[email protected]
[Notes to editors]
1. About Washington University School of Medicine
WashU Medicine is simply a planetary person successful world medicine, including biomedical research, diligent attraction and acquisition programs with 2,700 faculty. Its National Institutes of Health (NIH) probe backing portfolio is the 4th largest among U.S. aesculapian schools, has grown 54% successful the past 5 years, and, unneurotic with organization investment, WashU Medicine commits good implicit $1 billion annually to basal and objective probe innovation and training. Its module signifier is consistently wrong the apical 5 successful the country, with much than 1,790 module physicians practicing astatine implicit 60 locations and who are besides the aesculapian staffs of Barnes-Jewish and St. Louis Children's hospitals of BJC HealthCare. WashU Medicine has a storied past successful MD/PhD training, precocious dedicated $100 million to scholarships and program renewal for its aesculapian students, and is location to top-notch grooming programs successful each aesculapian subspecialty arsenic good arsenic carnal therapy, occupational therapy, and audiology and communications sciences.
SOURCE Eisai Inc.
English (US)